文献速递眼底病与葡萄膜炎青光眼

地塞米松植入物原位位置与眼压升高

INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
PubMed 文献 · Retina · 2018-01-01

这是一项回顾性研究,纳入2012至2016年至少接受一次玻璃体内地塞米松植入物注射、随访至少6个月且有植入物位置记录的患者,排除激素反应者、青光眼患者、玻璃体切除眼和玻璃体液化眼。共分析377例患者(432眼,257名男性,677次注射),88眼出现眼压升高,其中54眼植入物位于P1位置;P1位置与眼压升高>15 mmHg(P=0.004)及早期(<15天)发生的眼压升高相关(r=0.84,P<0.001)。结论为地塞米松植入物位于前部位置会增加眼压升高风险。

要点

  • 共分析377例患者432眼677次注射,88眼出现眼压升高。
  • 88眼眼压升高者中54眼植入物位于P1(与睫状体平坦部/睫状体区接触)。
  • P1位置与眼压升高>15 mmHg(P=0.004)及<15天早期发生眼压升高相关(r=0.84,P<0.001)。

核心结论

  • 地塞米松植入物位于前部位置会增加眼压升高(OHT)的风险。

研究设计与样本

  • 回顾性研究,纳入2012至2016年至少接受一次玻璃体内地塞米松植入物注射的患者,要求随访至少6个月且有植入物位置记录。
  • 排除激素反应者、青光眼患者、玻璃体切除眼和玻璃体液化眼;从患者病历中收集相关数据。
  • 植入物位置分为P1(与睫状体平坦部/睫状体区接触)、P2(涡静脉前方)和P3(涡静脉后方);眼压升高定义为绝对眼压>25 mmHg和/或眼压升高>10 mmHg。

主要发现

  • 共377例患者(432眼;257名男性;677次注射)符合分析条件,中位年龄57.24(±6.32)岁。
  • 88眼出现眼压升高,其中54眼植入物位于P1。
  • P1位置与眼压升高>15 mmHg相关(P=0.004),并与早期(<15天)发生的眼压升高相关(r=0.84,P<0.001)。

关键数值与推荐

  • 眼压升高定义为绝对眼压>25 mmHg和/或眼压升高>10 mmHg。
  • P1位置与眼压升高>15 mmHg相关(P=0.004)。
  • P1位置与早期(<15天)发生的眼压升高相关(r=0.84,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the association between the dexamethasone implant position in the vitreous cavity and ocular hypertension (OHT). METHODS: Retrospective review of patients with at least one intravitreal dexamethasone implant injection between 2012 and 2016. Patients who had a minimum follow-up for 6 months and documented evidence of the implant position were included in the study. Steroid responders, glaucoma patients, vitrectomized eyes, and eyes with liquefied vitreous were excluded. Relevant data were collected from patient charts. Three positions (P1, P2, and P3) were identified: P1 (in contact with the pars plana/ciliary body region), P2 (anterior to vortex veins), and P3 (posterior to vortex veins). Ocular hypertension was defined as absolute intraocular pressure > 25 mmHg and/or intraocular pressure rise > 10 mmHg. The relationship between implant position and intraocular pressure rise after factoring in other characteristics was the outcome measure. Appropriate statistical analysis was performed. RESULTS: A total of 377 patients (432 eyes; 257 males; 677 injections) were eligible for analysis. The median age was 57.24 (±6.32) years. Eighty-eight eyes had OHT. Of these, 54 eyes had the implant in P1. P1 was associated with high intraocular pressure response (>15 mmHg; P = 0.004) and early (<15 days) onset OHT (r = 0.84, P < 0.001). CONCLUSION: Anterior position of dexamethasone implant in situ increases the risk of OHT.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Sudhalkar A, Kodjikian L, Chhablani J, et al. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION. Retina. 2018. PMID: 29016454. doi:10.1097/IAE.0000000000001883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。